Andrew Denisuik
About
Andrew Denisuik is a scholar working on Molecular Medicine, Pharmacology and Epidemiology.
According to data from OpenAlex, Andrew Denisuik has authored 19 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Medicine, 9 papers in Pharmacology and 8 papers in Epidemiology. Recurrent topics in Andrew Denisuik's work include Antibiotic Resistance in Bacteria (18 papers), Antibiotics Pharmacokinetics and Efficacy (9 papers) and Bacterial Identification and Susceptibility Testing (7 papers). Andrew Denisuik is often cited by papers focused on Antibiotic Resistance in Bacteria (18 papers), Antibiotics Pharmacokinetics and Efficacy (9 papers) and Bacterial Identification and Susceptibility Testing (7 papers). Andrew Denisuik collaborates with scholars based in Canada and United States. Andrew Denisuik's co-authors include Heather J. Adam, George G. Zhanel, James A. Karlowsky, Philippe Lagacé‐Wiens, Andrew Walkty, Frank Schweizer, Daryl J. Hoban, Sheryl Zelenitsky, Joseph P. Lynch and Alfred S. Gin and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Journal of Antimicrobial Chemotherapy and Drugs.
In The Last Decade
Andrew Denisuik
19 papers receiving 1.4k citations
Peers
Andrew Denisuik
Eric Wenzler United States
Alyssa Golden Canada
Olympia Zarkotou Greece
Mari Ariyasu Japan
S. Bouchillon United States
Francesca Ginocchio Italy
Jared L. Crandon United States
Noriel Mariano United States
Anthony Harris United States
Katerina Themeli-Digalaki Greece
Citations per year, relative to Andrew Denisuik Andrew Denisuik (= 1×)
peers
Eric Wenzler
Countries citing papers authored by Andrew Denisuik
Since
Specialization
Citations
This map shows the geographic impact of Andrew Denisuik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Denisuik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Denisuik more than expected).
Fields of papers citing papers by Andrew Denisuik
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Andrew Denisuik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Denisuik. The network helps show where Andrew Denisuik may publish in the future.
Co-authorship network of co-authors of Andrew Denisuik
This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Denisuik. A scholar is included among the top collaborators of Andrew Denisuik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Denisuik. Andrew Denisuik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Zhanel, George G., Melanie Baxter, Philippe Lagacé‐Wiens, et al.. (2025). Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007–23). Journal of Antimicrobial Chemotherapy. 80(Supplement_2). ii15–ii26.
2.
Lagacé‐Wiens, Philippe, Laura Mataseje, Melissa McCracken, et al.. (2025). Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007–23. Journal of Antimicrobial Chemotherapy. 80(Supplement_2). ii45–ii53.
3.
Walkty, Andrew, James A. Karlowsky, Philippe Lagacé‐Wiens, et al.. (2022). Presence of the narrow-spectrum OXA-1 β-lactamase enzyme is associated with elevated piperacillin/tazobactam MIC values among ESBL-producing Escherichia coli clinical isolates (CANWARD, 2007–18). JAC-Antimicrobial Resistance. 4(2). dlac027–dlac027.
4.
Golden, Alyssa, James A. Karlowsky, Andrew Walkty, et al.. (2021). Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing Escherichia coli collected from Canadian hospitals: CANWARD 2007–18. Journal of Antimicrobial Chemotherapy. 76(11). 2825–2832.
5.
Karlowsky, James A., Andrew Walkty, Alyssa Golden, et al.. (2021). ESBL-positive Escherichia coli and Klebsiella pneumoniae isolates from across Canada: CANWARD surveillance study, 2007–18. Journal of Antimicrobial Chemotherapy. 76(11). 2815–2824.
6.
Karlowsky, James A., Heather J. Adam, Melanie Baxter, et al.. (2018). In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli. Antimicrobial Agents and Chemotherapy. 63(1).
7.
Denisuik, Andrew, Alyssa Golden, Heather J. Adam, et al.. (2018). Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study. Journal of Antimicrobial Chemotherapy. 74(3). 645–653.
8.
Zhanel, George G., Andrew Denisuik, Heather J. Adam, et al.. (2017). Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus Escherichia coli using an in vitro model. Diagnostic Microbiology and Infectious Disease. 88(3). 271–275.
9.
Zhanel, George G., Courtney K. Lawrence, Heather J. Adam, et al.. (2017). Imipenem–Relebactam and Meropenem–Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Drugs. 78(1). 65–98.
10.
Denisuik, Andrew, James A. Karlowsky, Wright W. Nichols, et al.. (2015). In Vitro Activity of Ceftazidime-Avibactam against 338 Molecularly Characterized Gentamicin-Nonsusceptible Gram-Negative Clinical Isolates Obtained from Patients in Canadian Hospitals. Antimicrobial Agents and Chemotherapy. 59(6). 3623–3626.
11.
Zhanel, George G., et al.. (2014). Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum -lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model. Journal of Antimicrobial Chemotherapy. 69(9). 2448–2452.
12.
Walkty, Andrew, Heather J. Adam, Melanie Baxter, et al.. (2014). In Vitro Activity of Plazomicin against 5,015 Gram-Negative and Gram-Positive Clinical Isolates Obtained from Patients in Canadian Hospitals as Part of the CANWARD Study, 2011-2012. Antimicrobial Agents and Chemotherapy. 58(5). 2554–2563.
13.
Sepehri, Shadi, Guillaume Poliquin, David A. Boyd, et al.. (2014). Osteomyelitis Due to Multiple Carbapenemase‐Producing Gram‐Negative Bacteria: The First Case Report of a GES‐13‐Producing Pseudomonas aeruginosa Isolate in Canada. Canadian Journal of Infectious Diseases and Medical Microbiology. 25(4). 229–231.
14.
Zhanel, George G., Heather J. Adam, Melanie Baxter, et al.. (2013). Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. Journal of Antimicrobial Chemotherapy. 68(suppl 1). i7–i22.
15.
Zhanel, George G., Phillip Chung, Heather J. Adam, et al.. (2013). Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli. Drugs. 74(1). 31–51.
16.
Denisuik, Andrew, Philippe Lagacé‐Wiens, Johann Pitout, et al.. (2013). Molecular epidemiology of extended-spectrum -lactamase-, AmpC -lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. Journal of Antimicrobial Chemotherapy. 68(suppl 1). i57–i65.
17.
Lagacé‐Wiens, Philippe, Heather J. Adam, Donald E. Low, et al.. (2013). Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007-11. Journal of Antimicrobial Chemotherapy. 68(suppl 1). i23–i29.
18.
Zhanel, George G., Heather J. Adam, Frank Schweizer, et al.. (2013). Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination. Drugs. 73(2). 159–177.
19.
Karlowsky, James A., Andrew Denisuik, Philippe Lagacé‐Wiens, et al.. (2013). In Vitro Activity of Fosfomycin against Escherichia coli Isolated from Patients with Urinary Tract Infections in Canada as Part of the CANWARD Surveillance Study. Antimicrobial Agents and Chemotherapy. 58(2). 1252–1256.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Eric Wenzler Breakdown of academic impact, for papers by Alyssa Golden Breakdown of academic impact, for papers by Olympia Zarkotou Breakdown of academic impact, for papers by Mari Ariyasu Breakdown of academic impact, for papers by S. Bouchillon Breakdown of academic impact, for papers by Francesca Ginocchio Breakdown of academic impact, for papers by Jared L. Crandon Breakdown of academic impact, for papers by Noriel Mariano Breakdown of academic impact, for papers by Anthony Harris Breakdown of academic impact, for papers by Katerina Themeli-Digalaki